PCM
AQST icon

Prelude Capital Management’s Aquestive Therapeutics AQST Stock Holding History

Prelude Capital Management’s Portfolio AQST Stock Details AQST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$212K Buy
51,054
+30,485
+148% +$124K 0.02% 883
2025
Q4 		$133K Sell
20,569
-17,904
-47% -$112K 0.01% 1145
2025
Q3 		$215K Sell
38,473
-26,229
-41% -$113K 0.02% 909
2025
Q2 		$214K Buy
64,702
+16,361
+34% +$46.9K 0.02% 786
2025
Q1 		$140K Buy
48,341
+36,409
+305% +$110K 0.01% 996
2024
Q4 		$42.5K Sell
11,932
-4,576
-28% -$21.1K ﹤0.01% 1153
2024
Q3 		$82.2K Sell
16,508
-71,882
-81% -$280K 0.01% 1177
2024
Q2 		$230K Buy
88,390
+63,594
+256% +$212K 0.02% 925
2024
Q1 		$106K Buy
+24,796
New +$82.5K 0.01% 1196
2019
Q1 		– Sell
-201
Closed -$1K – 1746
2018
Q4 		$1K Buy
+201
New +$2.54K ﹤0.01% 1706

Other funds holding AQST

BCM
Bratton Capital Management Fort Worth, Texas $40.7M AUM 43.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Prelude Capital Management's AQST Position: Q1 2026 in Review

Prelude Capital Management increased its Aquestive Therapeutics (AQST) stake by 148% in Q1 2026, buying an estimated $124K and bringing the position to 51,054 shares worth $212K. The position accounts for 0.02% of the portfolio, ranked #883.

Prelude Capital Management first reported a position in AQST in Q4 2018 and has held it in 10 quarters since. The position peaked at $230K in Q2 2024. 179 funds tracked by Wall St. Rank hold AQST as of Q1 2026.

  • Prelude Capital Management held 51,054 shares of Aquestive Therapeutics worth $212K as of Q1 2026.
  • Prelude Capital Management bought 30,485 Aquestive Therapeutics shares in Q1 2026, an estimated $124K.
  • Aquestive Therapeutics made up 0.02% of Prelude Capital Management's portfolio in Q1 2026, its #883 holding.
  • Prelude Capital Management first reported a position in Aquestive Therapeutics in Q4 2018 and has held it in 10 quarters since.
  • Prelude Capital Management's Aquestive Therapeutics position peaked at $230K in Q2 2024.
  • 179 funds tracked by Wall St. Rank held Aquestive Therapeutics as of Q1 2026.

Based on Prelude Capital Management's 13F filing for Q1 2026, filed 15 May 2026.